Giuseppe Ciaramella - 12 Dec 2022 Form 4/A - Amendment Insider Report for Beam Therapeutics Inc. (BEAM)

Role
President & CSO
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol
BEAM
Transactions as of
12 Dec 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
20 Dec 2022, 15:05:16 UTC
Date Of Original Report
14 Dec 2022
Previous filing
04 Apr 2022
Next filing
03 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -18,211 -67% $0.000000 9,106 12 Dec 2022 Common Stock 18,211 $0.6700 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 14, 2022, the reporting person filed a Form 4 which inadvertently attributed a stock option exercise to the incorrect stock option award. The stock option that was the subject of the reported exercise is the stock option award originally reported on September 9, 2021. Accordingly, the first line of Table 2 of this Form 4 reflects this correction.
F2 The stock option exercise was effected pursuant to a Rule 10b5-1 trading plan.
F3 The option award vests upon the achievement of a closing price hurdle following Beam Therapeutics Inc.'s initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.